A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a
lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of
lipid-conjugated peptide-based antigens [Amph-Peptides]) as adjuvant treatment of minimal
residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS)
mutated PDAC or other solid tumors.